Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4393 Target Snapshot

Macrophage metalloelastase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,056Compounds
191Assays
1Approved Drugs
1,074.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Macrophage metalloelastase shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P39900. Start with breast cancer, then reuse UniProt P39900 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P39900 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
breast cancer

Macrophage metalloelastase shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with breast cancer because it currently carries late clinical support. Linked drugs include MARIMASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Macrophage metalloelastase as ChEMBL target CHEMBL4393, mapped to UniProt P39900. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Macrophage metalloelastase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4393
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P39900
Macrophage metalloelastase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Macrophage metalloelastase is the right protein anchor across sources, using UniProt P39900 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMacrophage metalloelastase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP39900
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMacrophage metalloelastase
UniProt AccessionP39900
Component TypeProtein
Sequence Length470 aa

Macrophage metalloelastase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Macrophage metalloelastase, mapped to UniProt P39900. Sequence length is 470 aa.

Mapped IDP39900
Review nameMacrophage metalloelastase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Macrophage metalloelastase shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMARIMASTAT
Late clinical Phase III
lung cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMARIMASTAT
Clinical signal Phase II
chronic hepatitis C virus infection
1 linked drug · 1 direct · 1 efficacy
Linked drugCTS-1027
Clinical signal Phase II
chronic obstructive pulmonary disease
1 linked drug · 1 direct · 1 efficacy
Linked drugAZD-1236
Clinical signal Phase II
cystic fibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugAZD-1236
Clinical signal Phase II
hepatitis C virus infection
1 linked drug · 1 direct · 1 efficacy
Linked drugCTS-1027
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries late clinical support. Linked drugs include MARIMASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
2
Phase III
3
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50735.0
KI333.0
KD6.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4585243 10.07 IC50 0.085 Preclinical
CHEMBL1935285 10.0 IC50 0.1 Preclinical
CHEMBL1935286 10.0 IC50 0.1 Preclinical
CHEMBL5191016 9.72 Ki 0.19 Preclinical
CHEMBL507420 9.72 Ki 0.19 Preclinical
CHEMBL179288 9.7 IC50 0.2 Preclinical
CHEMBL573715 9.7 IC50 0.2 Preclinical
CHEMBL1935287 9.7 IC50 0.2 Preclinical
CHEMBL1935288 9.7 IC50 0.2 Preclinical
CHEMBL111856 9.62 IC50 0.24 Preclinical
Distribution

pChEMBL Value Distribution

59
5.0
57
5.5
90
6.0
96
6.5
119
7.0
106
7.5
103
8.0
41
8.5
21
9.0
14
9.5
pChEMBL
Assay Landscape

Assay Landscape

191
Total Assays
755
Tested Compounds
2
Assay Types
Binding — 183 assays, 755 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 161 665 6.8
assay format 17 47 7.6
cell-based format 5 43 7.3
ADME — 8 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 8 3 7.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine